Heart failure & cardiomyopathies
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Pooled result · NT-proBNP changeResult — go to the resultRatio of change 0.76 95% CI 0.69–0.83Authors' conclusion
In patients stabilized after WHF, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP and improved clinical outcome compared with control therapy, in particular across the spectrum of EF ≤60%.
Study context
- Population
- Patients hospitalised for HF or ≤30 days after a worsening HF event, after stabilisation, across the ejection fraction (EF) spectrum881 PIONEER-HF, 466 PARAGLIDE-HF
- Participants
- 1,347 patients
- Comparison
- Sacubitril/valsartan vs control therapy
- Outcome
- Time-averaged proportional change in NT-proBNP from baseline
- Follow-up
- Through weeks 4 and 8
Methodological detailsdouble-blind
- Double-blind
Pooled result
NT-proBNP change
Ratio of change
0.76
95% CI 0.69–0.83
P < 0.0001
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| CV death or HF hospitalisation · through end of follow-upAdjusted for trial | 0.70 (0.54–0.91) | P = 0.0077 | |
| 0.512Hazard ratio (log scale) |
CV death or HF hospitalisation · through end of follow-up
- Effect consistent across EF ≤60%
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Symptomatic hypotension | 1.35 (1.05–1.72) | |
| 0.512Relative risk (log scale) |
Original publication
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. J Am Coll Cardiol. Published 26 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →